Terazosin And Metabolic Engagement in Alzheimer's Disease

Part of paid clinical trials in Iowa City, Iowa.

Sponsor
Qiang Zhang
Study ID
NCT07796308
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Alzheimer s Disease

Eligibility Criteria

Sex
ALL
Age
50 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Terazosin (Hytrin) — DRUG
    In this double blind, randomized, placebo controlled phase IIa clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 78 weeks. Participants will start at 1mg daily for the first 2 weeks, then the dosage will be increased to 5mg daily over 6 weeks, and continued through the end of the study.
  • Placebo — OTHER
    In this double blind, randomized, placebo controlled phase IIa clinical trial, subjects randomized into the placebo group will receive placebo for 78 weeks.

Study Details

The TAME-AD trial will be a randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the metabolic target engagement of terazosin for the treatment of Alzheimer's disease.

Key Dates

First listed
Sep 1, 2026
Start date
Aug 1, 2027
Status verified
Aug 2026
Primary completion
Jul 31, 2031
Completion
Jul 31, 2032

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo
    Participants in this arm will receive placebo during the trial for 78 weeks, the placebo will follow the same schedule as the Terazosin group; the placebo capsules will have the same appearance as the Terazosin capsules.
  • Experimental: Terazosin
    Participants in this arm will receive Terazosin hydrochloride treatment for 78 weeks. Participants will start at 1mg daily for the first 2 weeks, then the dosage will be increased to 5mg daily over 6 weeks and continued through the end of the study.

Primary Outcome Measure

Whole blood ATP level [ Time Frame: At baseline, 2 weeks (TZ 1mg), 4weeks (2mg), 6 weeks (3mg), 8 weeks (4mg) , 10 weeks (5mg), and 78 weeks (5mg end of study) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of IowaIowa CityIowa52242
Qiang Zhang, MD
[email protected]
4154251369
Nandakumar Narayanan, MD PhD
[email protected]
3193561616
Qiang Zhang, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Iowa City, IA

By research site
University of Iowa· Iowa City, IA

Related Studies